insights_auto
Outlook: 48.6% bullish·0.0% bearish
Go to analysischevron_right
GILD:NASDAQ
Gilead Sciences, Inc
156,19 $
arrow_downward
-0,75%(-1,18) 1D
156,84 $
arrow_upward
+0,42% (+0,65)bedtimeAfter hours
Closed: 16 қаз., 16:00:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
157,32 $
High
157,58 $
Low
155,62 $
Mkt. cap
193,67 млрд
Avg. vol.
5,79 млн
Volume
7,77 млн
Dividend
2,10%
Quarterly dividend
0,82 $
Ex-dividend date
2026 ж. 15 қыр.
52-wk high
160,51 $
52-wk low
114,02 $
EPS
-2,66 $
Beta
0,32
Shares outstanding
1,24 млрд
No. of employees
17 мың
Open
157,32 $
High
157,58 $
Low
155,62 $
Mkt. cap
193,67 млрд
Avg. vol.
5,79 млн
Volume
7,77 млн
Dividend
2,10%
Quarterly dividend
0,82 $
Ex-dividend date
2026 ж. 15 қыр.
52-wk high
160,51 $
52-wk low
114,02 $
EPS
-2,66 $
Beta
0,32
Shares outstanding
1,24 млрд
No. of employees
17 мың
News stories
From web sources and news partners
MarketBeat
·
1 сағат бұрын
Gilead Sciences, Inc. $GILD Stake Cut by TD Waterhouse Canada Inc.
Simply Wall Street
·
13 сағат бұрын
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
15 сағат бұрын
Gilead chairman & CEO O’Day sells $2.2m in stock
Investing.com Nigeria
·
1 күн бұрын
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 мың
Founded1987 ж. 22 мау.
HeadquartersFoster City, Калифорния, Америка Құрама Штаттары
Sector-
Websitegilead.com